---
title: "Amsokigene autoleucel TIL Therapy Shows Promise in ICI-Resistant Advanced Melanoma Trials"
id: "nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04743-6"
published_at: "2026-11-03T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Amsokigene autoleucel TIL Therapy Shows Promise in ICI-Resistant Advanced Melanoma Trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04743-6)
- **Published At:** 2026-11-03T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- **Amsokigene autoleucel (amsoki-cel, OBX-115)** is an engineered tumor-infiltrating lymphocyte (TIL) therapy expressing membrane-bound interleukin-15 (mbIL15), regulated by acetazolamide (ACZ), avoiding need for interleukin-2. - Pooled data from two phase 1 and 1/2 single-arm trials including treatment of 37 patients with advanced melanoma resistant to immune checkpoint inhibitors (ICIs). - First-in-human (FIH) trial experienced rapid lymphocyte expansion and brain edema at initial dosing, leading to protocol revisions: dose de-escalation of amsoki-cel by 80% and ACZ by 75% followed by cautious re-escalation. - No dose-limiting toxicities, ICU admissions, or treatment-related deaths observed across studies. - Grade 3 or higher adverse events primarily hematologic: neutropenia (65%), leukopenia/lymphopenia (57%), anemia and thrombocytopenia (38%). - Serious adverse events in 27% of patients, evenly split between hematologic and non-hematologic events. - Recommended phase 2 dose (RP2D) selected based on tolerability and preliminary anti-tumor activity from phase 1 trials. - At RP2D, preliminary objective response rate (ORR) was 66.7% with two complete responses among 15 treated patients. - Engineered TIL therapy offers a potentially safer alternative to non-engineered TIL treatments requiring high-dose IL-2 and extensive lymphodepletion. - Ongoing pivotal phase 2 cohort will provide additional efficacy and safety data. - Trials identified as NCT05470283 and NCT06060613; source data does not report detailed dosing regimens or long-term outcomes.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04743-6#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04743-6) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials [ Download PDF ](https://www.nature.com/articles/s41591-026-04743-6.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04743-6.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 03 November 2026 # Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials * [Rodabe N. Amaria](https://www.nature.com/articles/s41591-026-04743-6#auth-Rodabe_N_-Amaria-Aff1) [ORCID: orcid.org/0000-0001-6876-278X](https://orcid.org/0000-0001-6876-278X)[1](https://www.nature.com/articles/s41591-026-04743-6#Aff1), * [Jason A. Chesney](https://www.nature.com/articles/s41591-026-04743-6#auth-Jason_A_-Chesney-Aff2)[2](https://www.nature.com/articles/s41591-026-04743-6#Aff2), * [Allison S. Betof](https://www.nature.com/articles/s41591-026-04743-6#auth-Allison_S_-Betof-Aff3) [ORCID: orcid.org/0000-0001-6422-2997](https://orcid.org/0000-0001-6422-2997)[3](https://www.nature.com/articles/s41591-026-04743-6#Aff3), * [Gino K. In](https://www.nature.com/articles/s41591-026-04743-6#auth-Gino_K_-In-Aff4)[4](https://www.nature.com/articles/s41591-026-04743-6#Aff4), * [Alexander N. Shoushtari](https://www.nature.com/articles/s41591-026-04743-6#auth-Alexander_N_-Shoushtari-Aff5-Aff6) [ORCID: orcid.org/0000-0002-8065-4412](https://orcid.org/0000-0002-8065-4412)[5](https://www.nature.com/articles/s41591-026-04743-6#Aff5),[6](https://www.nature.com/articles/s41591-026-04743-6#Aff6), * [Tirrell T. Johnson](https://www.nature.com/articles/s41591-026-04743-6#auth-Tirrell_T_-Johnson-Aff7)[7](https://www.nature.com/articles/s41591-026-04743-6#Aff7), * [Omid Hamid](https://www.nature.com/articles/s41591-026-04743-6#auth-Omid-Hamid-Aff8) [ORCID: orcid.org/0000-0002-8238-4655](https://orcid.org/0000-0002-8238-4655)[8](https://www.nature.com/articles/s41591-026-04743-6#Aff8), * [Yazan Samhouri](https://www.nature.com/articles/s41591-026-04743-6#auth-Yazan-Samhouri-Aff9)[9](https://www.nature.com/articles/s41591-026-04743-6#Aff9), * [Michael A. Davies](https://www.nature.com/articles/s41591-026-04743-6#auth-Michael_A_-Davies-Aff1) [ORCID: orcid.org/0000-0002-0977-0912](https://orcid.org/0000-0002-0977-0912)[1](https://www.nature.com/articles/s41591-026-04743-6#Aff1), * [Hussein A. Tawbi](https://www.nature.com/articles/s41591-026-04743-6#auth-Hussein_A_-Tawbi-Aff1) [ORCID: orcid.org/0000-0003-1942-851X](https://orcid.org/0000-0003-1942-851X)[1](https://www.nature.com/articles/s41591-026-04743-6#Aff1), * [Isabella C. Glitza Oliva](https://www.nature.com/articles/s41591-026-04743-6#auth-Isabella_C_-Glitza_Oliva-Aff1) [ORCID: orcid.org/0000-0002-4530-7765](https://orcid.org/0000-0002-4530-7765)[1](https://www.nature.com/articles/s41591-026-04743-6#Aff1), * [Bulent Arman Aksoy](https://www.nature.com/articles/s41591-026-04743-6#auth-Bulent_Arman-Aksoy-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10), * [Amanda M. Kelly](https://www.nature.com/articles/s41591-026-04743-6#auth-Amanda_M_-Kelly-Aff10) [ORCID: orcid.org/0009-0004-7316-3932](https://orcid.org/0009-0004-7316-3932)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10), * [Raina Duan](https://www.nature.com/articles/s41591-026-04743-6#auth-Raina-Duan-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10), * [Prakash Prabhakar](https://www.nature.com/articles/s41591-026-04743-6#auth-Prakash-Prabhakar-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10), * [Giridharan Ramsingh](https://www.nature.com/articles/s41591-026-04743-6#auth-Giridharan-Ramsingh-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10), * [Madan Jagasia](https://www.nature.com/articles/s41591-026-04743-6#auth-Madan-Jagasia-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10) & * … * [Parameswaran Hari](https://www.nature.com/articles/s41591-026-04743-6#auth-Parameswaran-Hari-Aff10)[10](https://www.nature.com/articles/s41591-026-04743-6#Aff10) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04743-6#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Amsokigene autoleucel (amsoki-cel, OBX-115) is a tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express acetazolamide (ACZ)-regulatable membrane-bound interleukin-15, abrogating the need for interleukin-2. In two single-arm trials (completed phase 1 single-center first-in-human (FIH) and ongoing phase 1/2 multicenter Agni-01), patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma received lymphodepletion and varying doses and schedules of amsoki-cel and ACZ. The primary objective of FIH and Agni-01 phase 1 was safety, tolerability and recommended phase 2 dose (RP2D); the primary objective of Agni-01 phase 2 was objective response rate (ORR) at the RP2D. The first patient treated experienced rapid lymphocyte expansion and vasogenic edema of a previously irradiated brain metastasis, prompting protocol modifications and dose deescalation in FIH, including 80% reduction in maximum amsoki-cel dose and 75% reduction in ACZ dose. After preliminary demonstration of safety at the lower dose, doses were increased in FIH, and reescalation was initiated in Agni-01. Across studies, 37 patients were treated (FIH, _n_ = 17; Agni-01, _n_ = 20). Post hoc pooled analysis demonstrated no dose-limiting toxicities, ICU care or treatment-related mortality. Most common grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (64.9% (24/37)), leukopenia/lymphopenia (56.8% (21/37) each) and anemia/thrombocytopenia (37.8% (14/37) each). Serious TEAEs were reported for 10 patients, including eight patients with grade 3 or higher events (non-hematologic, 13.5% (5/37); hematologic, 13.5% (5/37)). RP2D was selected based on overall safety and tolerability as well as preliminary anti-tumor activity in Agni-01 phase 1. The phase 2 preliminary ORR was 66.7% (6/9). In total, 15 patients were treated at RP2D and comprise the Key Efficacy Set (Agni-01: phase 1, _n_ = 6; phase 2, _n_ = 9), of which 10 patients (66.7%; 95% confidence interval 38−88%) achieved objective responses (including two complete responses). Amsoki-cel demonstrated favorable safety and promising early clinical activity in patients with ICI-resistant melanoma. A separate phase 2 pivotal Agni-01 cohort is ongoing. ClinicalTrials.gov identifiers: [NCT05470283](https://clinicaltrials.gov/study/NCT05470283) and [NCT06060613](https://clinicaltrials.gov/study/NCT06060613). ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Cytotoxic T cells](https://www.nature.com/subjects/cytotoxic-t-cells) * [Interleukins](https://www.nature.com/subjects/interleukins) * [Melanoma](https://www.nature.com/subjects/melanoma) * [Cancer Immunotherapy Through Tumor Cell Vaccines](https://www.nature.com/subjects/cancer-immunotherapy-through-tumor-cell-vaccines) ## Main ICIs have substantially improved overall survival in frontline advanced (unresectable or metastatic) melanoma[1](https://www.nature.com/articles/s41591-026-04743-6#ref-CR1 "Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11–22 https://doi.org/10.1056/NEJMoa2407417 \(2025\)."),[2](https://www.nature.com/articles/s41591-026-04743-6#ref-CR2 "Long, G. V. et al. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: overall survival and response rates from RELATIVITY-047 \(CA224-047\). J. Clin. Oncol. 40, 360385 \(2022\)."), yet most patients will experience disease progression and require subsequent therapy. Available post-ICI therapies demonstrate limited clinical benefit and substantial morbidity, underscoring the unmet need for novel therapeutics[3](https://www.nature.com/articles/s41591-026-04743-6#ref-CR3 "Joshi, U. M., Kashani-Sabet, M. & Kirkwood, J. M. Cutaneous melanoma: a review. JAMA 334, 2113–2125 https://doi.org/10.1001/jama.2025.13074 \(2025\)."). Adoptive cell therapy with tumor-derived autologous T cells (TILs) is an individualized cancer treatment involving one-time infusion of TILs expanded ex vivo from the patient’s own tumor tissue[4](https://www.nature.com/articles/s41591-026-04743-6#ref-CR4 "Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 https://doi.org/10.1056/NEJMoa2210233 \(2022\)."),[5](https://www.nature.com/articles/s41591-026-04743-6#ref-CR5 "Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte \(TIL\) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10, e005755 https://doi.org/10.1136/jitc-2022-005755 \(2022\)."). Non-engineered TIL cell therapy, pioneered in the pre-ICI era at the US National Institutes of Health in the 1980s[6](https://www.nature.com/articles/s41591-026-04743-6#ref-CR6 "Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676–1680 https://doi.org/10.1056/NEJM198812223192527 \(1988\)."), provided the foundation for further development by additional researchers. In the Netherlands, TIL cell therapy has been approved for reimbursement (January 2023) and, in the United States, has gained regulatory approval for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a programmed cell death protein 1 (PD-1)-blocking antibody and targeted therapy as indicated[7](https://www.nature.com/articles/s41591-026-04743-6#ref-CR7 "AMTAGVI \(lifileucel\). Accelerated BLA Approval https://www.fda.gov/media/176418/download?attachment \(Iovance Biotherapeutics, 2024\)."). Although many patients benefit, the impact of non-engineered TIL cell therapy is limited by requirements for surgical tumor tissue procurement (TTP), cardio-pulmonary fitness, standard-dose lymphodepletion (cumulative cyclophosphamide dose of 120 mg kg−1), high-dose interleukin-2 (IL-2)[8](https://www.nature.com/articles/s41591-026-04743-6#ref-CR8 "Betof Warner, A. et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J. Immunother. Cancer 12, e008735 https://doi.org/10.1136/jitc-2023-008735 \(2024\).") and regimen-related toxicity, including treatment-related mortality (TRM)[9](https://www.nature.com/articles/s41591-026-04743-6#ref-CR9 "AMTAGVI \(lifileucel\) \(package insert\) https://www.fda.gov/media/176417/download \(Iovance Biotherapeutics, 2024\)."),[10](https://www.nature.com/articles/s41591-026-04743-6#ref-CR10 "Martín-Lluesma, S. et al. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann. Oncol. 36, 909–919 https://doi.org/10.1016/j.annonc.2025.04.001 \(2025\)."). High-dose intravenous IL-2 remains an essential component of non-engineered TIL expansion and anti-tumor efficacy[11](https://www.nature.com/articles/s41591-026-04743-6#ref-CR11 "Dudley, M. E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243–251 \(2002\)."), and systemic administration of IL-2 can induce substantial clinical toxicity[5](https://www.nature.com/articles/s41591-026-04743-6#ref-CR5 "Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte \(TIL\) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10, e005755 https://doi.org/10.1136/jitc-2022-005755 \(2022\)."),[6](https://www.nature.com/articles/s41591-026-04743-6#ref-CR6 "Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676–1680 https://doi.org/10.1056/NEJM198812223192527 \(1988\).") that can limit patient eligibility[8](https://www.nature.com/articles/s41591-026-04743-6#ref-CR8 "Betof Warner, A. et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J. Immunother. Cancer 12, e008735 https://doi.org/10.1136/jitc-2023-008735 \(2024\)."). Amsoki-cel (OBX-115) is an investigational engineered autologous TIL cell therapy that expresses membrane-bound interleukin-15 (mbIL15) under pharmacologic regulation using a carbonic anhydrase-2 (CA2) drug-responsive domain (DRD). In the basal state, the mbIL15−DRD fusion protein is degraded in the proteasome due to mutations in the _CA2_ gene that cause intentional misfolding. Upon administration of the small-molecule drug ACZ, the DRD is stabilized, and mbIL15 is expressed on the cell surface (Extended Data Fig. [1](https://www.nature.com/articles/s41591-026-04743-6#Fig5))[12](https://www.nature.com/articles/s41591-026-04743-6#ref-CR12 "Model List of Essential Medicines. World Health Organization https://list.essentialmeds.org/ "),[13](https://www.nature.com/articles/s41591-026-04743-6#ref-CR13 "Pedro, K. D. et al. Abstract LB096: IL15-engineered tumor infiltrating lymphocytes \(cytoTIL15TM\) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2. Cancer Res. 83, LB096 https://doi.org/10.1158/1538-7445.Am2023-lb096 \(2023\)."),[14](https://www.nature.com/articles/s41591-026-04743-6#ref-CR14 "Burga, R. A. et al. IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol. Ther. 33, 3605–3623
## Related Clinical Research

- [VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers](https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of.md)
- [Ipilimumab plus Nivolumab Yields 50% Observed ORR in Small WD‑NET Phase II Cohort](https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine.md)
- [Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis](https://medichelpline.com/clinical-feed/pubmed-42934318.md) (DOI: 10.1007/s10143-026-04538-w)
- [Relatlimab plus nivolumab 5-year outcomes in advanced melanoma: RELATIVITY-047 survival and biomar](https://medichelpline.com/clinical-feed/nature-0-relatlimab-plus-nivolumab-versus-nivolumab-for-advanced-melanoma-5-year.md)
- [Spatial transcriptomics links lipid and mitochondrial metabolism to T cell exclusion in esophageal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-spatial-transcriptomic-sequencing-identifies-lipid-metabolism-and-mitochondrial.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.